A plan by the National Institutes of Health to award an exclusive license for a CAR-T therapy that was funded by U.S. taxpayers to a group of biotech venture capitalists has sparked concerns among advocacy groups over pricing and access in the U.S. and elsewhere.

At issue are patent rights for an acute myeloid leukemia treatment the agency recently indicated would be awarded to an obscure company called ElevateBio, which was created by four current or former partners at MPM Capital. The venture capital firm has invested in dozens of companies, including 23andMe and Pharmasset, which is credited with discovering the breakthrough Sovaldi hepatitis C medicine.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy